Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Reduced by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 9.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,644 shares of the medical research company’s stock after selling 6,920 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Edwards Lifesciences were worth $6,064,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. 9258 Wealth Management LLC grew its stake in Edwards Lifesciences by 24.8% in the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock valued at $803,000 after purchasing an additional 2,093 shares in the last quarter. Gryphon Financial Partners LLC boosted its stake in shares of Edwards Lifesciences by 35.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock worth $492,000 after acquiring an additional 1,698 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Edwards Lifesciences by 5.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,172,836 shares of the medical research company’s stock worth $89,433,000 after acquiring an additional 58,442 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Edwards Lifesciences by 2.9% during the 4th quarter. Janney Montgomery Scott LLC now owns 76,614 shares of the medical research company’s stock worth $5,842,000 after acquiring an additional 2,126 shares in the last quarter. Finally, Great Lakes Advisors LLC boosted its stake in shares of Edwards Lifesciences by 4.5% during the 4th quarter. Great Lakes Advisors LLC now owns 14,150 shares of the medical research company’s stock worth $1,079,000 after acquiring an additional 611 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $4,378,659.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $1,218,138 in the last 90 days. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the subject of several recent analyst reports. UBS Group decreased their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Barclays decreased their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Oppenheimer reiterated an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday. Finally, StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Fifteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $80.29.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $68.52 on Friday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $41.28 billion, a P/E ratio of 29.53, a P/E/G ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a 50 day moving average of $72.39 and a two-hundred day moving average of $83.47.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the company earned $0.66 EPS. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.